JP6397550B1 - Constitution improver - Google Patents

Constitution improver Download PDF

Info

Publication number
JP6397550B1
JP6397550B1 JP2017174465A JP2017174465A JP6397550B1 JP 6397550 B1 JP6397550 B1 JP 6397550B1 JP 2017174465 A JP2017174465 A JP 2017174465A JP 2017174465 A JP2017174465 A JP 2017174465A JP 6397550 B1 JP6397550 B1 JP 6397550B1
Authority
JP
Japan
Prior art keywords
amla
lingonberry
extract
constitution
improving agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017174465A
Other languages
Japanese (ja)
Other versions
JP2019048787A (en
Inventor
太郎 内山
太郎 内山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Priority to JP2017174465A priority Critical patent/JP6397550B1/en
Priority to PCT/JP2018/033365 priority patent/WO2019054313A1/en
Application granted granted Critical
Publication of JP6397550B1 publication Critical patent/JP6397550B1/en
Publication of JP2019048787A publication Critical patent/JP2019048787A/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/45Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/47Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

【課題】日常的な疲労感等の症状に対し、すぐれた改善効果を有するとともに、継続的な経口摂取が可能な天然由来で安全性の高い有効成分を配合した体質改善剤の提供。【解決手段】リンゴンベリー(別名:コケモモ)とアムラ(別名:余柑子、油柑、アンマロク、インディアングーズベリー等)の植物体又はその抽出物を含有する体質改善剤。【選択図】図1An object of the present invention is to provide a constitution improving agent containing a natural-derived highly safe active ingredient that has an excellent improving effect on symptoms such as daily fatigue and can be continuously ingested. [Solution] A constitution improving agent comprising plants of Lingonberry (also known as bilberry) and Amla (also known as citrus, oil citrus, ammarok, Indian gooseberry) or an extract thereof. [Selection] Figure 1

Description

本発明は、リンゴンベリー(Vaccinium vitis-idaea)とアムラ(Phyllanthus emblica又はEmblica officinale)の植物体又はその抽出物を含有した、食品又は医薬品に有用な体質改善剤に関する。   The present invention relates to a constitution improving agent useful for foods or pharmaceuticals, which contains plants of Lingonberry (Vaccinium vitis-idaea) and Amla (Phyllanthus emblica or Emblica officinale) or extracts thereof.

働く人の多くは、疲労感やだるさ、慢性的な消化器系の不快感、睡眠不足などに悩まされており、特に女性は、これら症状に加え、手足の冷え、肌の不調などの症状が、日常的な悩みとなっている。   Many working people suffer from fatigue, dullness, chronic gastrointestinal discomfort, sleep deprivation, etc. Especially women have symptoms such as cold limbs and skin problems in addition to these symptoms. , Has become a daily trouble.

このような日常的かつ慢性的な症状を総合的に緩和あるいは治療するため、漢方薬が服用されることが多いが、その効果は長期間服用することによって徐々に現れるため、症状のすばやい改善を求めることは困難である。   Kampo medicine is often taken to comprehensively relieve or treat such daily and chronic symptoms, but the effect gradually appears after long-term use, and prompt improvement of symptoms is sought. It is difficult.

一方、各症状に対し西洋医薬を服用することも可能ではあるが、予防薬として日常的に服用することは困難であり、長期間に服用した場合には副作用等による弊害が生じる危険性も考えられる。   On the other hand, it is possible to take western medicine for each symptom, but it is difficult to take it as a preventive medicine on a daily basis, and there is a risk that adverse effects such as side effects will occur if taken for a long time. It is done.

このため、日常的な疲労感等の症状に対して、すぐれた効果を有するとともに、継続的な経口摂取が可能な天然由来で安全性の高い有効成分を配合した体質改善剤の開発が求められる。   For this reason, it is necessary to develop a constitution improving agent that has an excellent effect on daily symptoms such as fatigue and that contains a naturally-derived and safe active ingredient that can be continuously taken orally. .

特開2009−292738号公報JP 2009-292738

本発明の目的は、日常的な疲労感等の症状に対し、すぐれた改善効果を有するとともに、継続的な経口摂取が可能な天然由来で安全性の高い有効成分を配合した体質改善剤を提供することにある。   The object of the present invention is to provide a constitution improving agent containing a naturally occurring and highly safe active ingredient that has an excellent improving effect on symptoms such as daily fatigue and can be continuously ingested. There is to do.

本発明者は、上記課題を解決するために鋭意検討を行った結果、ツツジ科スノキ属(Vaccinium)のリンゴンベリー(Vaccinium vitis-idaea)とトウダイグサ科エンブリカ属(Emblica)のアムラ(Phyllanthus emblica又はEmblica officinale)の植物体又はその抽出物を継続的に服用した場合、疲労、睡眠、むくみ、肩のこり、手足の冷えが効果的に改善されることを見い出し、本発明を完成するに至った。 As a result of intensive studies to solve the above problems, the present inventor has found that the Vaccinium genus Vaccinium (Vaccinium vitis-idaea) and the Euphorbiaceae Emblica Amla (Phyllanthus emblica or Emblica) The present inventors have found that fatigue, sleep, swelling, stiff shoulders, and cold hands and feet are effectively improved when an officinale) plant or an extract thereof is continuously taken, and the present invention has been completed.

すなわち、本発明は、リンゴンベリー(Vaccinium vitis-idaea)とアムラ(Phyllanthus emblica又はEmblica officinale)の植物体又はその抽出物を含有することを特徴とする、疲労、睡眠、むくみ、肩のこり、又は手足の冷えのいずれかを改善するための体質改善剤である。 That is, the present invention comprises fatigue, sleep, swelling, stiff shoulders, limbs or limbs characterized by containing plant bodies of Lingonberry (Vaccinium vitis-idaea) and Amla (Phyllanthus emblica or Emblica officinale) or extracts thereof. It is a constitution improving agent for improving any of the cold .

本発明の体質改善剤によれば、継続的に服用した場合、疲労、睡眠、むくみ、肩のこり、又は手足の冷えのいずれかを効果的に改善し、健康的で良好な状態を維持することが可能となる。 According to the constitution-improving agent of the present invention, when taken continuously, it effectively improves fatigue, sleep, swelling, stiff shoulders, or cold limbs, and maintains a healthy and good state. Is possible.

体質改善の効果を示すグラフGraph showing the effect of constitution improvement

本発明の体質改善剤は、経口摂取することが可能なツツジ科スノキ属(Vaccinium)のリンゴンベリー(Vaccinium vitis-idaea)とトウダイグサ科エンブリカ属(Emblica)のアムラ(Phyllanthus emblica又はEmblica officinale)から得られる植物体又はその抽出物を有効成分として含有する。   The constitution improving agent of the present invention is obtained from a Vaccinium lingonberry (Vaccinium vitis-idaea) that can be taken orally and an Amla (Phyllanthus emblica or Emblica officinale). The obtained plant body or its extract is contained as an active ingredient.

リンゴンベリー(Vaccinium vitis-idaea)は、別名コケモモと呼ばれ、北欧の北極圏やカナダに数多く自生し、ビタミンC やクエン酸を豊富に含むことが知られている。果実は、生食されるとともに、ジュース、ジャムなどの加工食品に常用されている。   Lingonberry (Vaccinium vitis-idaea), also known as cowberry, is known to be abundant in the Arctic Circle of Canada and Canada, and is rich in vitamin C and citric acid. Fruits are eaten raw and are commonly used in processed foods such as juice and jam.

本発明に用いられるリンゴンベリーの部位としては、特に限定されるものでないが、果実(未熟果実、完熟果実、乾燥果実)、葉、塊根、花、種子等、任意に用いられ得る。中でも果実が好ましく用いられる。   The part of the lingonberry used in the present invention is not particularly limited, but can be arbitrarily used for fruits (immature fruit, ripe fruit, dried fruit), leaves, tuberous roots, flowers, seeds and the like. Of these, fruits are preferably used.

本発明に用いるリンゴンベリーは生のままでも乾燥したものでも使用することができるが、使用性、製剤化等の点から乾燥粉末あるいは溶媒抽出物として用いることが好ましい。   The lingon berries used in the present invention can be used as raw or dried, but are preferably used as a dry powder or a solvent extract from the viewpoints of usability and formulation.

乾燥粉末を得る方法としては、植物の各種部位(果実、葉、塊根、花、種子等)あるいは全草を細断又は粉砕し、その後に乾燥する方法や植物を乾燥した後に細断又は粉砕して乾燥粉末を得る方法がある。また、植物を細断又は粉砕し、発酵や酵素処理を施した後、乾燥し、更に必要に応じて所定の粒径にすべく粉砕する方法等を適宜採ることができる。   As a method for obtaining a dry powder, various parts of plants (fruits, leaves, tuberous roots, flowers, seeds, etc.) or whole plants are shredded or pulverized, and then dried or chopped or ground after the plants are dried. There is a method to obtain a dry powder. Moreover, after chopping or grinding | pulverizing a plant, performing fermentation or an enzyme treatment, it can dry, and also the method of grind | pulverizing so that it may become a predetermined particle size as needed can be taken suitably.

リンゴンベリーの抽出物は常法より得ることができ、例えば、リンゴンベリーを必要により乾燥した後、抽出溶媒に一定期間浸漬するか、あるいは加熱還流している抽出溶媒と接触させ、次いで濾過し、濃縮して得ることができる。抽出溶媒としては、通常抽出に用いられる溶媒であれば任意に用いることができ、例えば、水、メタノール、エタノール、プロピレングリコール、1,3−ブチレングリコール、グリセリン等のアルコール類、クロロホルム、ジクロルエタン、四塩化炭素、アセトン、酢酸エチル等の有機溶媒を、それぞれ単独あるいは組み合わせて用いることができる。上記溶媒で抽出して得た抽出液をそのまま、あるいは濃縮したエキスを用いるか、あるいはこれらエキスを吸着法、例えばイオン交換樹脂を用いて不純物を除去したものや、ポーラスポリマー(例えばアンバーライトXAD−2)のカラムにて吸着させた後、メタノールまたはエタノールで溶出し、濃縮したものも使用することができる。また分配法、例えば水/酢酸エチルで抽出した抽出物等も用いられる。リンゴンベリー抽出物は、例えば「リンゴンベリーエキス」(オリザ油化(株)製)等として市販されており、これら市販品を用いてもよい。   The extract of lingonberry can be obtained by a conventional method. For example, after the lingonberry is dried as necessary, it is immersed in an extraction solvent for a certain period of time, or is contacted with an extraction solvent that is heated to reflux, and then filtered. It can be obtained by concentrating. As the extraction solvent, any solvent that is usually used for extraction can be used. For example, water, methanol, ethanol, propylene glycol, 1,3-butylene glycol, glycerol and other alcohols, chloroform, dichloroethane, four Organic solvents such as carbon chloride, acetone and ethyl acetate can be used alone or in combination. The extract obtained by extraction with the above solvent is used as it is, or concentrated extracts are used, or these extracts are removed by using an adsorption method, for example, ion exchange resin, or a porous polymer (for example, Amberlite XAD- After adsorbing on the column of 2), elution with methanol or ethanol and concentration can also be used. Further, a partitioning method, for example, an extract extracted with water / ethyl acetate can be used. The lingonberry extract is commercially available, for example, as “Lingonberry extract” (manufactured by Oriza Oil Chemical Co., Ltd.), and these commercially available products may be used.

本発明で用いるアムラ(Phyllanthus emblica又はEmblica officinale)は、トウダイグサ科コミカンソウ属(Emblica)に属する落葉の亜高木で、インドからマレーシア地域および中国南部にかけて分布しており、インドが原産地と考えられている。アムラは各地方または言語によりそれぞれ固有の名称を有しており、例えば、余柑子、油柑、アンマロク、マラッカノキ、インディアングーズベリー等とも称されている。   Amla (Phyllanthus emblica or Emblica officinale) used in the present invention is a deciduous sub-tree belonging to the genus Emblica, distributed from India to Malaysia and southern China, and is considered to be the origin of India . Amla has a unique name depending on each region or language, and is also called, for example, citrus citrus, oil citrus, ammarok, malach, Indian gooseberry, and the like.

アムラの使用部位としては、特に限定されるものではなく、果実(未熟果実、完熟果実、乾燥果実)、葉、塊根、花、種子等、任意に用いることができるが、中でも果実が好ましく用いられる。   The use site of Amla is not particularly limited, and can be used arbitrarily such as fruits (immature fruits, ripe fruits, dried fruits), leaves, tuberous roots, flowers, seeds, among which fruits are preferably used. .

アムラは生のままでも乾燥したものでも使用することができるが、使用性、製剤化等の点から乾燥粉末あるいは溶媒抽出物として用いることが好ましい。乾燥粉末や抽出物を得るための方法は、特に限定されるものでなく、上記リンゴンベリーで記した方法を採用することができる。アムラ抽出物は、例えば太陽化学(株)から「サンアムラ」等として市販もされており、これら市販品を用いてもよい。   Amla can be used raw or dried, but it is preferably used as a dry powder or a solvent extract from the viewpoints of usability and formulation. The method for obtaining the dry powder or the extract is not particularly limited, and the method described in the above lingon berry can be employed. Amla extract is also commercially available, for example, as “San Amla” from Taiyo Kagaku Co., Ltd., and these commercially available products may be used.

本発明の体質改善剤は、各種飲食品に配合し食品として摂取することができ、また、医薬製剤として投与することができる。   The constitution improving agent of the present invention can be mixed with various foods and drinks and taken as food, and can be administered as a pharmaceutical preparation.

本発明の体質改善剤は、各種飲食品にリンゴンベリーとアムラの植物体又はその抽出物を配合しても得ることができるが、量産工程においては、前記体質改善剤を仕掛品とし、これを各種飲食品に配合してもよい。   The constitution improving agent of the present invention can be obtained by blending various lingon berry and amla plants or extracts thereof into various foods and drinks, but in the mass production process, the constitution improving agent is used as an in-process item. You may mix | blend with various food-drinks.

摂取(投与)するリンゴンベリーとアムラの量は、摂取(投与)する方法や剤型等に応じて、適宜決めることができるが、一日当たりの摂取(投与)量を、乾燥質量換算でリンゴンベリーについては0.1mg〜10g、好ましくは1〜1000mg、最も好ましくは10〜100mgとし、アムラについては、0.1mg〜10g、好ましくは1〜1000mg、最も好ましくは10〜100mgとするように調製することが望ましい。   The amount of Lingonberry and Amla to be ingested (administered) can be appropriately determined according to the method of ingestion (administration), dosage form, etc., but the amount of ingestion (administration) per day can be determined in terms of dry mass. 0.1 mg to 10 g, preferably 1 to 1000 mg, most preferably 10 to 100 mg. Amla is prepared to 0.1 mg to 10 g, preferably 1 to 1000 mg, most preferably 10 to 100 mg. It is desirable.

本発明の体質改善剤を飲食品に配合する場合には、必要に応じて添加剤を任意に選択し併用することができる。添加剤としては機能性素材、賦形剤、呈味剤を含ませることができる。   When mix | blending the constitution improving agent of this invention with food-drinks, an additive can be arbitrarily selected as needed and used together. As additives, functional materials, excipients, and flavoring agents can be included.

機能性素材としては、パントテン酸、葉酸、ビオチンなど各種ビタミン類、亜鉛、カルシウム、マグネシウム、鉄など各種ミネラル類、アミノ酸、オリゴ糖、プロポリス、ローヤルゼリー、イチョウ葉、ウコン、EPA、DHA、コエンザイムQ10、コンドロイチン、乳酸菌、ラクトフェリン、イソフラボン、プルーン、キチン、キトサン、グルコサミン、α−リポ酸、アガリクス、ガルシニア、プロポリス、コラーゲン、アスタキサンチン、フォースリン、カテキン、セサミン、セラミド、モロヘイヤ、スピルリナ、キャッツクローなどが挙げられる。これらの機能性素材は、単独で又は二種以上で組み合わせて使用できる。   Functional materials include various vitamins such as pantothenic acid, folic acid and biotin, various minerals such as zinc, calcium, magnesium and iron, amino acids, oligosaccharides, propolis, royal jelly, ginkgo biloba, turmeric, EPA, DHA, coenzyme Q10, Chondroitin, lactic acid bacteria, lactoferrin, isoflavone, prunes, chitin, chitosan, glucosamine, α-lipoic acid, agaricus, garcinia, propolis, collagen, astaxanthin, forthrin, catechin, sesamin, ceramide, moroheiya, spirulina, cats claw, etc. . These functional materials can be used alone or in combination of two or more.

賦形剤としては、所望の剤型とするときに通常用いられるものであれば何でも良く、例えば、コムギデンプン、コメデンプン、トウモロコシデンプン、バレイショデンプン、デキストリン、シクロデキストリンなどのでんぷん類、結晶セルロース類、乳糖、ブドウ糖、砂糖、還元麦芽糖、水飴、フラクトオリゴ糖、乳化オリゴ糖などの糖類、ソルビトール、エリスリトール、キシリトール、ラクチトール、マンニトールなどの糖アルコール類が挙げられる。これら賦形剤は、単独で又は二種以上組み合わせて使用できる。   The excipient may be anything that is usually used in the desired dosage form, for example, starches such as wheat starch, rice starch, corn starch, potato starch, dextrin, cyclodextrin, and crystalline celluloses. , Sugars such as lactose, glucose, sugar, reduced maltose, starch syrup, fructooligosaccharide, emulsified oligosaccharide, and sugar alcohols such as sorbitol, erythritol, xylitol, lactitol, mannitol. These excipients can be used alone or in combination of two or more.

呈味剤としては、ボンタンエキス、ライチエキス、ゆずエキス等の各種果汁エキス、リンゴ果汁、オレンジ果汁、レモン果汁等の各種果汁、ピーチフレーバー、ウメフレーバー、ヨーグルトフレーバー等の各種フレーバー、アセスルファムK、スクラロース、エリスリトール、オリゴ糖類、マンノース、キシリトール、異性化糖類等の各種甘味料、クエン酸、リンゴ酸、酒石酸、グルコン酸等の各種酸味料、緑茶、ウーロン茶、バナバ茶、杜仲茶、鉄観音茶、ハトムギ茶、アマチャヅル茶、マコモ茶、昆布茶等の各種茶成分等が挙げられる。これら呈味剤は、単独で又は二種以上組み合わせて使用できる。   As a flavoring agent, various fruit juice extracts such as Bontang extract, lychee extract and yuzu extract, various fruit juices such as apple juice, orange juice and lemon juice, various flavors such as peach flavor, ume flavor and yogurt flavor, acesulfame K, sucralose , Erythritol, oligosaccharides, mannose, xylitol, isomerized sugars, and other sweeteners, citric acid, malic acid, tartaric acid, gluconic acid, and other acidulants, green tea, oolong tea, banaba tea, Tochu tea, iron kannon tea, pearl barley Various tea ingredients such as tea, amacha mul tea, macomo tea, and kelp tea are listed. These taste agents can be used alone or in combination of two or more.

その他の着色剤、保存剤、増粘剤、結合剤、崩壊剤、分散剤、安定化剤、ゲル化剤、酸化防止剤、界面活性剤、保存剤、pH調整剤等については、食品等に使用される公知のものを適宜選択して使用できる。   Other colorants, preservatives, thickeners, binders, disintegrants, dispersants, stabilizers, gelling agents, antioxidants, surfactants, preservatives, pH adjusters, etc. A known one to be used can be appropriately selected and used.

飲食品の形態としては、例えば、液体状、固形状、顆粒状、粒状、ペースト状、ゲル状など任意に選択することができる。   The form of the food or drink can be arbitrarily selected from, for example, liquid, solid, granule, granular, paste, and gel.

飲食品の具体例として、例えば、果汁飲料、野菜ジュース、清涼飲料、茶等の飲料類、スープ、プリン、ヨーグルト、ケーキプレミックス製品、菓子類、クッキー、キャンディー、グミ、ガム等の各種一般加工食品のほか、ドリンク剤などの栄養補助飲食品、特定保健用飲食品、機能性飲食品、健康飲食品などが挙げられる。ただしこれら例示に限定されるものでない。   Specific examples of foods and beverages include, for example, fruit juice beverages, vegetable juices, soft drinks, beverages such as tea, soups, pudding, yogurt, cake premix products, confectionery, cookies, candy, gummi, gum, and other general processing In addition to foods, food supplements such as drinks, foods and drinks for specified health use, functional foods and drinks, and health foods and drinks are included. However, it is not limited to these examples.

本発明の体質改善剤を医薬製剤として用いる場合、剤型は適宜選択できるが、例えば錠剤、顆粒剤、散剤、カプセル剤等の固形製剤や、内服液剤、シロップ剤等の液体製剤等とすることができ、これらの医薬製剤には、通常用いられる結合剤、崩壊剤、増粘剤、分散剤、再吸収促進剤、矯味剤、緩衝剤、界面活性剤、溶解補助剤、保存剤、乳化剤、等張化剤、安定化剤やpH調製剤などの賦形剤を適宜使用してもよい。   When the constitution improving agent of the present invention is used as a pharmaceutical preparation, the dosage form can be appropriately selected. For example, it can be a solid preparation such as a tablet, a granule, a powder or a capsule, or a liquid preparation such as an internal solution or a syrup. These pharmaceutical preparations include commonly used binders, disintegrants, thickeners, dispersants, reabsorption accelerators, taste-masking agents, buffers, surfactants, solubilizers, preservatives, emulsifiers, Excipients such as isotonic agents, stabilizers and pH adjusters may be used as appropriate.

以下、本発明の効果を確認するために行った試験及び結果ついてさらに詳細に説明するが、本発明は以下の試験例あるいは実施例に限定されるものではない。   Hereinafter, although the test and result which were performed in order to confirm the effect of the present invention are explained in detail, the present invention is not limited to the following test examples or examples.

パネラーによる連用テストを行い、以下に示す試験により本発明の効果を確認した。連用テストは、4種類の試験試料(ドリンク)を用意し、A〜D群に分かれて実施した。パネラーの数は、A群39名、B群8名、C群14名、D群39名である。各パネラーは試験試料(ドリンク)を1日1本、経口摂取により服用した。   A panel test was conducted, and the effects of the present invention were confirmed by the following tests. In the continuous test, four types of test samples (drinks) were prepared and divided into groups A to D. The number of panelists is A group 39 people, B group 8 people, C group 14 people, D group 39 people. Each paneler took a test sample (drink) by ingestion once a day.

試験試料(ドリンク)の処方を表1に示す。   Table 1 shows the formulation of the test sample (drink).

Figure 0006397550
Figure 0006397550

試験1「アンケート評価」
(試験方法)
連用テスト開始前と連用テスト開始28日後において、「疲れやすさ」、「疲労の回復度合い」、「朝の目覚めやすさ」、「ぐっすり眠れる」、「体が重くだるい」、「筋肉痛のなりやすさ」、「足のむくみ」、「朝の顔のむくみ」、「肩のこり」、「手足の冷え」、「ほてりやホットフラッシュ」、「二日酔いのなりやすさ」に関する項目についてアンケート調査を実施した。
Test 1 “Questionnaire Evaluation”
(Test method)
Before the start of the continuous test and 28 days after the start of the continuous test, “Ease of fatigue”, “Degree of recovery from fatigue”, “Ease of waking up in the morning”, “Sleep well”, “Heavily heavy”, “Muscle pain” Surveys were conducted on items related to ease, swelling of feet, swelling of morning faces, stiff shoulders, cold limbs, hot flashes and hot flashes, and hangover proneness. did.

アンケートは、評価尺度として汎用されているVAS(視覚的アナログ尺度(visual analogue scale)の略称)により評価した。すなわち、それぞれの調査日に、被験者に10cmの横一直線に引いた直線を記載した用紙を配布し、直線の左端を「一番悪い状態」、右端を「一番良い状態」として、実感できる程度を直線上の位置として記入(被験者が線分上の一箇所に印を付す)してもらい、試験開始の位置を基準として右側(又は左側)に移動した距離を尺度値として評価した。尚、群間差を検証するための統計解析はTukeyにて実施した。   The questionnaire was evaluated by VAS (abbreviation for visual analogue scale) which is widely used as an evaluation scale. That is, on each survey day, a paper describing a straight line drawn in a 10 cm horizontal line is distributed to the subjects, and the left end of the straight line is “worst state” and the right end is “best state”. Was entered as a position on the straight line (subject marked a place on the line segment), and the distance moved to the right (or left) from the test start position was evaluated as a scale value. In addition, statistical analysis for verifying the difference between groups was performed by Tukey.

図1に示すように、D群(リンゴンベリーとアムラ配合)は、A群(プラセボ)、B群(アムラ単独配合)、C群(リンゴンベリー単独配合)のいずれと比較しても、すべての項目においてすぐれた効果を発揮することが確認された。   As shown in FIG. 1, Group D (Lingonberry and Amla combination) is all compared to Group A (placebo), Group B (Amla alone combination), and Group C (Lingonberry alone combination). It was confirmed that an excellent effect was exhibited in the item.

Figure 0006397550
Figure 0006397550

また表2は、A群(プラセボ)、B群(アムラ単独配合)、C群(リンゴンベリー単独配合)、D群(リンゴンベリーとアムラ配合)の群間差を統計解析により検証した結果を示す。表中、***印は有意確率p<0.001による有意差、**印は有意確立p<0.01による有意差、*印は有意確率p<0.05による有意差、+印は有意確率p<0.1による有意な傾向差が認められたことを示す。

Table 2 shows the results of statistical analysis of the differences between group A (placebo), group B (amla alone), group C (lingonberry alone), and group D (lingonberry and amla). . In the table, *** indicates a significant difference with significance probability p <0.001, ** indicates a significant difference with significance established p <0.01, * indicates a significant difference with significance probability p <0.05, + indicates a significance probability p <0.1. It shows that a significant trend difference was observed.

表2の結果から、D群(リンゴンベリーとアムラ配合)は、A群(プラセボ)に対して、すべての項目において有意差があることが認められた。また、D群(リンゴンベリーとアムラ配合)は、B群(アムラ単独配合)、C群(リンゴンベリー単独配合)に対しても、ほぼすべての項目において有意差あるいは有意な傾向差が認められ、リンゴンベリーとアムラを配合することによる相乗効果を確認することができた。   From the results of Table 2, it was recognized that the D group (containing Lingonberry and Amla) was significantly different from the A group (placebo) in all items. In addition, Group D (Lingonberry and Amla combination) is significantly different from Group B (Amla alone) and Group C (Lingonberry alone) in almost all items. The synergistic effect by combining lingonberry and amla could be confirmed.

以下に、ドリンク以外の体質改善剤の処方例を示すが、これらは単なる一例であり本発明を限定するものではない。   Although the example of a constitution improving agent other than a drink is shown below, these are only examples and do not limit the present invention.

処方例1:タブレット(1日分)
(1)リンゴンベリー抽出物(乾燥質量換算) 25mg
(2)アムラ抽出物(乾燥質量換算) 30mg
(3)調整油(鐚瓶E含有)(加工でんぷん) 36mg
(4)ビタミンC 200mg
(5)ビタミンB2 8mg
(6)ビタミンB6 20mg
(7)ショ糖エステル 40mg
(8)結晶セルロース 126mg
(9)コーンスターチ 適量
合計 2g
Formulation Example 1: Tablet (for 1 day)
(1) Lingonberry extract (dry mass conversion) 25mg
(2) Amla extract (dry mass conversion) 30mg
(3) Adjusted oil (contains jar E) (processed starch) 36mg
(4) Vitamin C 200mg
(5) Vitamin B2 8mg
(6) Vitamin B6 20mg
(7) Sucrose ester 40mg
(8) Crystalline cellulose 126mg
(9) Cornstarch proper amount total 2g

処方例2:カプセル(1日分)
(1)リンゴンベリー抽出物(乾燥質量換算) 25mg
(2)アムラ抽出物(乾燥質量換算) 30mg
(3)ステアリン酸カルシウム 24mg
(4)二酸化ケイ素 12mg
(5)澱粉 適量
(6)被包剤 192mg
合計 1.2g
Formulation Example 2: Capsule (for 1 day)
(1) Lingonberry extract (dry mass conversion) 25mg
(2) Amla extract (dry mass conversion) 30mg
(3) Calcium stearate 24mg
(4) Silicon dioxide 12mg
(5) Appropriate amount of starch
(6) Encapsulation 192mg
Total 1.2g

処方例3:ゼリー(1日分)
(1)リンゴンベリー抽出物(乾燥質量換算) 25mg
(2)アムラ抽出物(乾燥質量換算) 30mg
(3)エリスリトール 6.75g
(4)ゲル化剤 1.35g
(5)ビタミンC 360mg
(6)ビタミンB2 0.75mg
(7)ビタミンB6 0.75mg
(8)甘味料 45mg
(9)酸味料 195mg
(10)香料 165mg
(11)精製水 適量
合計 150g
Formulation Example 3: Jelly (for 1 day)
(1) Lingonberry extract (dry mass conversion) 25mg
(2) Amla extract (dry mass conversion) 30mg
(3) Erythritol 6.75g
(4) Gelling agent 1.35g
(5) Vitamin C 360mg
(6) Vitamin B2 0.75mg
(7) Vitamin B6 0.75mg
(8) Sweetener 45mg
(9) Acidulant 195mg
(10) Fragrance 165mg
(11) Appropriate amount of purified water 150g in total

Claims (1)

リンゴンベリー(Vaccinium vitis-idaea)とアムラ(Phyllanthus emblica又はEmblica officinale)の植物体又はその抽出物を含有することを特徴とする、疲労、睡眠、むくみ、肩のこり、又は手足の冷えのいずれかを改善するための体質改善剤。 Any of fatigue, sleep, swelling, stiff shoulders, or cold limbs , characterized by containing Lingonberry (Vaccinium vitis-idaea) and Amla (Phyllanthus emblica or Emblica officinale) plants or extracts thereof Constitution improver to improve.
JP2017174465A 2017-09-12 2017-09-12 Constitution improver Active JP6397550B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2017174465A JP6397550B1 (en) 2017-09-12 2017-09-12 Constitution improver
PCT/JP2018/033365 WO2019054313A1 (en) 2017-09-12 2018-09-10 Agent for improving physical condition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017174465A JP6397550B1 (en) 2017-09-12 2017-09-12 Constitution improver

Publications (2)

Publication Number Publication Date
JP6397550B1 true JP6397550B1 (en) 2018-09-26
JP2019048787A JP2019048787A (en) 2019-03-28

Family

ID=63668560

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017174465A Active JP6397550B1 (en) 2017-09-12 2017-09-12 Constitution improver

Country Status (2)

Country Link
JP (1) JP6397550B1 (en)
WO (1) WO2019054313A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012173010A1 (en) * 2011-06-15 2012-12-20 株式会社資生堂 Platelet-derived growth factor (pdgf)-bb production-enhancing agent, and stem cell stabilizer containing same
WO2013005514A1 (en) * 2011-07-06 2013-01-10 株式会社 資生堂 Skin-improving agent for oral intake

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012173010A1 (en) * 2011-06-15 2012-12-20 株式会社資生堂 Platelet-derived growth factor (pdgf)-bb production-enhancing agent, and stem cell stabilizer containing same
WO2013005514A1 (en) * 2011-07-06 2013-01-10 株式会社 資生堂 Skin-improving agent for oral intake

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FRAGRANCE JOURNAL, vol. 37, no. 9, JPN6018016329, September 2009 (2009-09-01), pages 39 - 49 *
伊藤正男ほか編, 医学書院 医学大辞典, vol. 第1版, JPN6018016326, 1 March 2003 (2003-03-01), pages 15 - 3 *
日本臨牀, vol. 第45巻, 第8号, JPN6018016327, 1987, pages 1741 - 1746 *

Also Published As

Publication number Publication date
WO2019054313A1 (en) 2019-03-21
JP2019048787A (en) 2019-03-28

Similar Documents

Publication Publication Date Title
KR101498780B1 (en) Composition for preventing or treating hangover
JP6640392B2 (en) Obesity control composition
KR102448542B1 (en) Composition for relieving menopausal symptom
KR101490786B1 (en) Composition comprising water extracts from fomitella fraxinea (fr.) imaz. for treating or preventing obesity
KR101017594B1 (en) Preparation of fermented onion containing increased quercetin content
JP4917180B1 (en) Skin improver for ingestion
KR20180040534A (en) Antioxidant or anti-aging composition comprising extracts of fresh sprouts of Xanthium canadense Mill.
KR20100128941A (en) Functional composition for the prevention and improvement of hangover, and food and food additive having the same
KR20180042936A (en) a composition comprising the mycelium culture medium from Schizophyllum commune as an active ingredient for preventing or treating liver disease and alleviating hangover
JP2015502954A (en) A composition for preventing or treating dyslipidemia, comprising an aqueous extract of Aguitake as an active ingredient
JP6397550B1 (en) Constitution improver
KR101636608B1 (en) Composition for antioxidation comprising the seed extract of cornus officinalis
KR20170077980A (en) Antioxidant or anti-aging composition comprising extracts of fresh sprouts of Xanthium canadense Mill.
JP6044944B2 (en) Process for producing new processed ume products and functional composition, food composition, and pharmaceutical composition using the same
KR102006551B1 (en) Composition for Removing Hangover Using an Extract of Enteromorpha prolifera, Sprout Ginseng etc.
KR100690071B1 (en) Functional composition for the prevention and improvement of hangover
KR101338532B1 (en) Composition for preventing or treating colon cancer containing extract of sea cucumber
JP4608017B1 (en) Pore reducing agent for oral consumption
KR20190125616A (en) Method for producing inner beauty beverage using Chrysanthemum zawadskii and fermeted Rhus verniciflua
KR20130065117A (en) Composition comprising water extracts from tremella foliacea fr. for treating or preventing obesity
KR102012170B1 (en) Composition comprising extracts of banana, cherry, and walnut for anti-skin aging
KR20180006612A (en) Compositions for preventing or treating diabetes mellitus comprising extract of Aster koraiensis or fraction thereof
KR101074348B1 (en) Anti-helicobacter composition containing green algae extract
KR101490792B1 (en) Composition comprsing alcohol extracts from hapalopilus rutilans for treating or preventing obesity
JP2013116887A (en) Oral hair growth agent

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180727

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180828

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180831

R150 Certificate of patent or registration of utility model

Ref document number: 6397550

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150